Team:Amplino/Home

From 2012e.igem.org

(Difference between revisions)
(Contact Us)
(Amplino project outlines)
Line 10: Line 10:
'''Target Market''': bottom-of-the-pyramid in developing countries
'''Target Market''': bottom-of-the-pyramid in developing countries
-
'''Product''': an affordable, mobile, easy to use, diagnostic tool for malaria
+
'''Challenge''': inadequate Malaria diagnostics, especially for pregnant women
-
'''Business Model''': economically incentify improvement of health in a local community
+
'''Solution''': an affordable, mobile, easy to use, diagnostic device for Malaria
 +
 
 +
'''Business Model''': stimulate entrepreneurship and economically incentify improvement of health in a local community
On this wiki we will present our deliverables for the iGEM Entrepreneurship competition. For more information on our business, please visit the [http://www.amplino.org/ Amplino website].
On this wiki we will present our deliverables for the iGEM Entrepreneurship competition. For more information on our business, please visit the [http://www.amplino.org/ Amplino website].

Revision as of 10:23, 21 October 2012

Amplino project outlines

At Amplino we believe biotech and business combine best when one keeps things simple. Here's a brief overview of our project:

Goal: set up a sustainable biotech business

Vision: make high tech low cost

Mission: make a real impact on the world

Target Market: bottom-of-the-pyramid in developing countries

Challenge: inadequate Malaria diagnostics, especially for pregnant women

Solution: an affordable, mobile, easy to use, diagnostic device for Malaria

Business Model: stimulate entrepreneurship and economically incentify improvement of health in a local community

On this wiki we will present our deliverables for the iGEM Entrepreneurship competition. For more information on our business, please visit the [http://www.amplino.org/ Amplino website].

Contact Us

For any inquiries regarding this iGEM Entrepreneurship project, please contact us at info@amplino.org. Also, take a look at our press page.

Twitter